SEC Comment Letter 0000000000-24-001739 to Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX)

Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Feb. 13, 2024 · CIK: 0001671502 · Accession: 0000000000-24-001739

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-277016

Date

February 13, 2024

Author

Not clearly detected

Form

UPLOAD

Company

Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)

Letter

United States securities and exchange commission logo February 13, 2024 Dr. Michael Myers Chief Executive Officer Quoin Pharmaceuticals, Ltd. 42127 Pleasant Forest Court Ashburn, VA 20148-7349 Re:Quoin Pharmaceuticals, Ltd. Registration Statement on Form S-1 Filed February 12, 2023 File No. 333-277016 Dear Dr. Michael Myers: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Ansart at 202-551-4511 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Melissa Palat Murawsky

Show Raw Text

United States securities and exchange commission logo
February 13, 2024
Dr. Michael Myers
Chief Executive Officer
Quoin Pharmaceuticals, Ltd.
42127 Pleasant Forest Court
Ashburn, VA 20148-7349
Re:Quoin Pharmaceuticals, Ltd.
Registration Statement on Form S-1
Filed February 12, 2023
File No. 333-277016
Dear Dr. Michael Myers:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Ansart at 202-551-4511 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Melissa Palat Murawsky

SecProbe.io